Bass AR, Abdel-Wahab N, Reid PD, Sparks JA, Calabrese C, Jannat-Khah DP et al (2023) Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis 82(7):920–926

Article  CAS  PubMed  Google Scholar 

Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326

Article  CAS  PubMed  Google Scholar 

Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H (2009) IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway. J Exp Med 206(7):1457

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao J, Chen X, Herjan T, Li X (2020) Cytokines focus: the role of interleukin-17 in tumor development and progression. J Exp Med 217(1):e20190297

Article  PubMed  Google Scholar 

Chen YS, Huang TH, Liu CL, Chen HS, Lee MH, Chen HW et al (2019) Locally targeting the IL-17/IL-17RA axis reduced tumor growth in a murine B16F10 melanoma model. Hum Gene Ther 30(3):273–285

Article  CAS  PubMed  Google Scholar 

Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W et al (2021) The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol 185(5):935–944

Article  CAS  PubMed  Google Scholar 

Li PH, Wai Chan SC, Lau CS, Yan Seto MT, Chung HY (2022) Conventional and biologic disease-modifying antirheumatic drugs are not associated with increase in or progression of cervical neoplasia among patients with spondyloarthritis. J Clin Rheumatol 28(1):E63–E68

Article  PubMed  Google Scholar 

Pellegrini C, Esposito M, Rossi E, Gisondi P, Piaserico S, Dapavo P et al (2022) Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study. Dermatol Ther (Heidelb). 12(11):2613

Article  PubMed  PubMed Central  Google Scholar 

Tekgoz E, Colak S, Yardimci KG, Kucuksahin O, Cinar M, Yilmaz S et al (2022) Physicians’ biological drug preference in patients with rheumatoid arthritis and spondyloarthritis with a history of malignancy: perspectives from the treasure database. J Clin Rheumatol 28(2):E318–E323

Article  PubMed  Google Scholar 

Monsour EP, Pothen J, Balaraman R. A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report. Cureus [Internet]. 2019 Oct 2 [cited 2023 Dec 2];11(10). Available from: https://pubmed.ncbi.nlm.nih.gov/31754559/

Ma VT, Lao CD, Fecher LA, Schiopu E (2022) Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy 14(8):593–598

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rudwaleit M, Van Der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777–783

Article  CAS  PubMed  Google Scholar 

Rudwaleit M, Van Der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25–31

Article  CAS  PubMed  Google Scholar 

Esfahani K, Miller WH (2017) Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 376(20):1989–1991

Article  PubMed  Google Scholar 

Saura SP, Casimiro LM, Vázquez AG, Benavent MP, Guillén-Climent S, Villaescusa EM (2021) Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies. Dermatol Online J. https://doi.org/10.5070/D327654071

Article  Google Scholar 

Vinaixa-Aranzazu A, Morillas-Lahuerta V, Blanco-De-Tord M, Carrascosa-Carrillo JM (2021) Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient. Eur J Dermatol 31(4):564–565

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong C (2008) IL-23/IL-17 biology and therapeutic considerations. J Immunotoxicol 5(1):43–46

Article  PubMed  Google Scholar 

Zhao J, Chen X, Herjan T, Li X (2020) The role of interleukin-17 in tumor development and progression. J Exp Med. https://doi.org/10.1084/jem.20190297

Article  PubMed  PubMed Central  Google Scholar